For a number of reasons, 2009 was a big year for the atrial fibrillation ablation market. Early in the year, Biosense Webster received FDA approval for its radiofrequency ablation catheter, the first such device to launch in the US with a specific AF indication. That approval was much more than just a landmark event for J&J; it changed the landscape of the AF industry, reinvigorating interest in the funding and development of new catheter-based technologies--a trend that has extended through to 2010 and will likely continue in the years ahead.
by Ariana Del Negro and Mary Thompson
For a number of reasons, 2009 was a big year for the atrial fibrillation (AF) ablation market. Early in the year, Biosense Webster Inc. (a division of Johnson...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
